All CIRM Grants

Search Filters »

Institution Researcher name Grant Type Grant Title Award Value
Ankasa Regenerative Therapeutics, Inc. Ying Zhu Late Stage Preclinical Projects IND-enabling development of ART352-L, an endogenous stem cell reactivation therapy to enhance bone healing in the elderly $3,987,693
City of Hope, Beckman Research Institute Xiuli Wang Late Stage Preclinical Projects CMV-specific T cells expressing anti-HIV CAR and CMV vaccine boost as immunotherapy for HIV/AIDS $3,812,797
University of California, San Francisco Dr. Krystof Bankiewicz Late Stage Preclinical Projects MRI Guided Delivery of Neural Progenitor Cells Secreting GDNF for the Treatment of Parkinson’s disease $5,757,078
Poseida Therapeutics, Inc. Devon J Shedlock Late Stage Preclinical Projects Late-Stage Preclinical Study of CAR-T Memory Stem Cells Targeting PSMA (P-PSMA-101) for the Treatment of Castrate-Resistant Metastatic Prostate Cancer $3,992,090
City of Hope, Beckman Research Institute Dr. Angelo Manuel Almeida Cardoso Ph.D., MD Late Stage Preclinical Projects Ex Vivo Gene Engineering of Blood Stem Cells for Enhanced Chemotherapy Efficacy in Glioblastoma Patients $3,684,259
University of California, Irvine Dr. Leslie M Thompson Late Stage Preclinical Projects An hESC-derived hNSC Therapeutic for Huntington’s Disease $5,635,393
Fate Therapeutics, Inc. Dr Bob Valamehr Late Stage Preclinical Projects IND enabling development of FT516: A Natural Killer Cell Immunotherapy for Cancer Derived from a Human Inducible Pluripotent Stem Cell $4,000,000
Stanford University Dr. Matthew H Porteus Late Stage Preclinical Projects Genome Editing of Autologous Hematopoietic Stem Cells to Treat Sickle Cell Disease $4,849,363
Cellerant Therapeutics, Inc. Swapna Panuganti Late Stage Preclinical Projects Development of CLT030-ADC, a Leukemic Stem Cell Targeting Antibody-Drug-Conjugate, for Treatment of Acute Myeloid Leukemia $6,863,755
Cellular Biomedicine Group, Inc. Jack J. Wang Late Stage Preclinical Projects Allogenic human adipose-derived mesenchymal stem cells for the treatment of knee osteoarthritis $1,200,000
Stanford University Dr. Gary Steinberg Late Stage Preclinical Projects Intraparenchymal NR1 Stem Cell Therapy for Chronic Subcortical Ischemic Stroke $5,300,000
University of California, San Diego Dr. Stephanie Cherqui Late Stage Preclinical Projects Ex vivo transduced autologous human CD34+ hematopoietic stem cells for treatment of cystinosis $5,273,189
University of California, Los Angeles Dr. Sophie X Deng Late Stage Preclinical Projects Regeneration of a Normal Corneal Surface by Limbal Stem Cell Therapy $4,244,211
ViaCyte, Inc. Dr. Tim Kieffer Late Stage Preclinical Projects Stem cell-derived islet cell replacement therapy with immunosuppression for high-risk type 1 diabetes $3,544,721
University of California, San Francisco Dr Jennifer M Puck Late Stage Preclinical Projects Ex Vivo Transduction of the Human Artemis (DCLRE1C) cDNA by Lentiviral Vector AProArt into CD34+ Hematopoietic Cells for Artemis (ART)-Deficient Severe Combined Immunodeficiency (SCID) $4,268,865
Angiocrine Bioscience, Inc. Dr. Paul W Finnegan Late Stage Preclinical Projects Development of AB-110: genetically-modified endothelial cells plus expanded cord blood hematopoietic stem cells as a transplantation therapy $3,797,117
Calibr Peter G Schultz Late Stage Preclinical Projects Development of a Chondrogenic Drug Candidate Targeting Resident Mesenchymal Stem Cells for the Treatment of Osteoarthritis $1,667,832
Cedars-Sinai Medical Center Shaomei Wang Late Stage Preclinical Projects IND-enabling study of subretinal delivery of human neural progenitor cells for the treatment of retinitis pigmentosa $4,954,514
Calibr Peter G Schultz Preclinical Development Awards Development of a Chondrogenic Drug Candidate Targeting Cartilage-residing Mesenchymal Stem Cells for the Treatment of Osteoarthritis $2,306,703
Scripps Health Dr. Darryl D. D’Lima Preclinical Development Awards Embryonic Stem Cell-Derived Chondroprogenitor Cells to Repair Osteochondral Defects $7,660,211
University of California, Davis Dr. Roslyn Rivkah Isseroff Preclinical Development Awards Scaffold for dermal regeneration containing pre-conditioned mesenchymal stem cells to heal chronic diabetic wounds $4,620,144
University of California, Irvine Dr. Leslie M Thompson Preclinical Development Awards A hNSC Development Candidate for Huntington’s Disease $4,951,623
Stanford University Dr. Matthew H Porteus Preclinical Development Awards Pre-clinical development of gene correction therapy of hematopoietic stem cells for SCID-X1 $874,877
University of California, Davis Dr. Diana L. Farmer Preclinical Development Awards Placental Stem Cells for the In Utero Treatment of Spina Bifida $2,182,146
Salk Institute for Biological Studies Dr. David R Schubert Preclinical Development Awards Human Stem-Cell Based Development of a Potent Alzheimer’s Drug Candidate $1,664,885
ViaCyte, Inc. Howard Foyt Accelerated Development Pathway I Clinical Development of a Cell Therapy for Diabetes $8,783,852
University of California, San Diego Catriona Jamieson Alpha Stem Cell Clinics Alpha Stem Cell Clinic for the Development of Regenerative Therapies $8,679,137
University of California, Los Angeles John S. Adams Alpha Stem Cell Clinics UCLA-UCI Alpha Stem Cell Clinic (ASCC) Consortium $8,680,000
City of Hope, Beckman Research Institute Prof. John A Zaia Alpha Stem Cell Clinics The Innovation-Alpha Clinic for Cellular Therapies (I-ACT) – A Program for the Development and Delivery of Innovative Cell-based Treatments and Cures for Life-threatening Diseases. $8,416,531
University of California, Davis Dr. J. Kent Leach Tools and Technologies III Multi-modal technology for non-destructive characterization of bioengineered tissues $1,574,151
University of Southern California Dr. Qilong Ying Tools and Technologies III Embryonic stem cell-based generation of rat models for assessing human cellular therapies $1,326,979
Stanford University Sarah Heilshorn Tools and Technologies III Injectable Hydrogels for the Delivery, Maturation, and Engraftment of Clinically Relevant Numbers of Human Induced Pluripotent Stem Cell-Derived Neural Progenitors to the Central Nervous System $1,347,767
Stanford University Dr. James C. Dunn Dr. Tools and Technologies III Skin-derived precursor cells for the treatment of enteric neuromuscular dysfunction $772,098
University of California, Los Angeles Dr. James C. Dunn Dr. Tools and Technologies III Skin-derived precursor cells for the treatment of enteric neuromuscular dysfunction $1,044,423
University of California, San Diego Dr. Shyni Varghese Tools and Technologies III Technologies to improve in vivo function of transplanted stem cells $1,373,683
University of California, San Diego Shaochen Chen Tools and Technologies III Development of 3D Bioprinting Techniques using Human Embryonic Stem Cells Derived Cardiomyocytes for Cardiac Tissue Engineering $1,368,264
University of California, Irvine Dr. Mathew Mark Blurton-Jones Tools and Technologies III Optimizing the differentiation and expansion of microglial progenitors from human pluripotent stem cells for the study and treatment of neurological disease. $1,147,596
University of California, Davis Dr. Laura Marcu Tools and Technologies III Multimodal platform combining optical and ultrasonic technologies for in vivo nondestructive evaluation of engineered vascular tissue constructs $1,834,350
University of Southern California Dr. Paula M. Cannon Tools and Technologies III Site-specific gene editing in hematopoietic stem cells as an anti-HIV therapy $1,495,665
City of Hope, Beckman Research Institute Joseph D Gold Tools and Technologies III Development of a scalable, practical, and transferable GMP-compliant suspension culture-based differentiation process for cardiomyocyte production from human embryonic stem cells. $891,518
Stanford University Dr. Fan Yang PhD Tools and Technologies III Injectable Macroporous Matrices to Enhance Stem Cell Engraftment and Survival $1,434,235
University of California, Berkeley Dr. David V. Schaffer Tools and Technologies III Engineered Biomaterials for Scalable Manufacturing and High Viability Implantation of hPSC-Derived Cells to Treat Neurodegenerative Disease $1,239,276
Stanford University Dr. Joseph C. Wu Tools and Technologies III Macaca mulatta as advanced model for predictive preclinical testing of engineered cardiac autografts and allografts $1,689,744
Stanford University Dr. Anthony E. Oro Tools and Technologies III A Chromatin Context Tool for Predicting iPS Lineage Predisposition and Tissue Graftability $1,391,125
University of California, Los Angeles Dr. Hanna Mikkola Tools and Technologies III A suite of engineered human pluripotent stem cell lines to facilitate the generation of hematopoietic stem cells $1,382,400
University of California, San Francisco Dr. Andrew D. Leavitt MD Tools and Technologies III Small molecule tools and scale-up technologies to expand human umbilical cord blood stem and progenitor cells for clinical and research use $1,416,600
Stanford University Dr. Irving L Weissman MD Tools and Technologies III Identification and isolation of transplantable human hematopoietic stem cells from pluripotent cell lines; two steps from primitive hematopoiesis to transplantable definitive cells, and non-toxic conditioning of hosts for hematopoeitic stem cell transp… $1,271,952
University of California, Los Angeles Dr. Carla M. Koehler Tools and Technologies III A small molecule tool for reducing the malignant potential in reprogramming human iPSCs and ESCs $1,283,900
University of Southern California Dr. Toshio Miki Tools and Technologies III Development of a clinical-grade extracorporeal liver support system using human induced pluripotent stem cell-derived hepatic cells $1,257,011
Scripps Research Institute Dr. Jeanne F Loring Tools and Technologies III User-friendly predictive molecular diagnostic assays for quality control of stem cell derivatives for transplantation and drug discovery $1,728,390
1 2 3 4 5 6 7 8 9 10 11 30